NASDAQ:ABVX ABIVAX Société Anonyme (ABVX) Stock Price, News & Analysis $11.30 -0.25 (-2.16%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get ABIVAX Société Anonyme alerts: Email Address About ABIVAX Société Anonyme Stock (NASDAQ:ABVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ABIVAX Société Anonyme alerts:Sign Up Key Stats Today's Range$11.20▼$11.6950-Day Range$10.85▼$13.7552-Week Range$7.99▼$17.02Volume41,402 shsAverage Volume81,856 shsMarket Capitalization$711.10 millionP/E RatioN/ADividend YieldN/APrice Target$36.50Consensus RatingModerate Buy Company OverviewABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Read More… The Perfect Storm for an EV Revolt (Ad)With constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves... Not many people realize there’s a "perfect storm" for profits unfolding in the auto industry - today. Or that cars and trucks are actually the world’s biggest business. Click here for details... ABIVAX Société Anonyme Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 48th PercentileABIVAX Société Anonyme scored higher than 48% of companies evaluated by MarketBeat, and ranked 596th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingABIVAX Société Anonyme has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageABIVAX Société Anonyme has only been the subject of 1 research reports in the past 90 days.Read more about ABIVAX Société Anonyme's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ABIVAX Société Anonyme are expected to decrease in the coming year, from ($2.80) to ($2.81) per share.Price to Book Value per Share RatioABIVAX Société Anonyme has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.35% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 16.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldABIVAX Société Anonyme does not currently pay a dividend.Dividend GrowthABIVAX Société Anonyme does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.35% of the float of ABIVAX Société Anonyme has been sold short.Short Interest Ratio / Days to CoverABIVAX Société Anonyme has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ABIVAX Société Anonyme has recently increased by 16.34%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.69 News SentimentABIVAX Société Anonyme has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for ABIVAX Société Anonyme this week, compared to 2 articles on an average week.Search Interest4 people have searched for ABVX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ABIVAX Société Anonyme insiders have not sold or bought any company stock.Percentage Held by Institutions47.91% of the stock of ABIVAX Société Anonyme is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ABIVAX Société Anonyme's insider trading history. Receive ABVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ABIVAX Société Anonyme and its competitors with MarketBeat's FREE daily newsletter. Email Address ABVX Stock News HeadlinesABIVAX Société Anonyme (0RA9.L)September 18 at 9:11 AM | nz.finance.yahoo.comABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest UpdateSeptember 17 at 3:39 AM | americanbankingnews.comForget Trump and KamalaI hope you're deleting all those emails telling you how to make "1,000% gains" from the magic "Kamala Trade". It's nonsense. No one knows what's going to happen in November.September 20, 2024 | Investors Alley (Ad)ABIVAX Société Anonyme (2X10.SG)September 13, 2024 | uk.finance.yahoo.comFY2024 EPS Estimates for ABIVAX Société Anonyme (NASDAQ:ABVX) Lifted by Leerink PartnrsSeptember 13, 2024 | americanbankingnews.comAbivax presents first-half 2024 financial resultsSeptember 9, 2024 | globenewswire.comAbivax SA ADR (ABVX)August 21, 2024 | investing.comAbivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment MilestoneAugust 6, 2024 | globenewswire.comSee More Headlines ABVX Stock Analysis - Frequently Asked Questions How have ABVX shares performed this year? ABIVAX Société Anonyme's stock was trading at $10.70 on January 1st, 2024. Since then, ABVX shares have increased by 5.6% and is now trading at $11.30. View the best growth stocks for 2024 here. When did ABIVAX Société Anonyme IPO? ABIVAX Société Anonyme (ABVX) raised $217 million in an initial public offering (IPO) on Friday, October 20th 2023. The company issued 18,699,460 shares at a price of $11.60 per share. Who are ABIVAX Société Anonyme's major shareholders? ABIVAX Société Anonyme's top institutional shareholders include Great Point Partners LLC (3.93%), Nantahala Capital Management LLC (1.57%), HighVista Strategies LLC (0.08%) and Sandia Investment Management LP (0.01%). How do I buy shares of ABIVAX Société Anonyme? Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ABVX Previous SymbolNASDAQ:ABVX CUSIPN/A CIK1956827 Webwww.abivax.com Phone33-1-53-83-09-63FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Stock Price Target$36.50 High Stock Price Target$50.00 Low Stock Price Target$16.00 Potential Upside/Downside+223.0%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.48 Current Ratio3.04 Quick Ratio4.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.37 per share Price / Book3.35Miscellaneous Outstanding Shares62,929,000Free FloatN/AMarket Cap$711.10 million OptionableNot Optionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ABVX) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABIVAX Société Anonyme Please log in to your account or sign up in order to add this asset to your watchlist. Share ABIVAX Société Anonyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.